Home Away From Home - Medical Outcomes
NCT02774850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 610
Last updated 2019-12-23
Summary
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. Infectious complications are the leading cause of treatment related mortality among AML patients, but there are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. The primary objective of this study is to compare the clinical effectiveness of outpatient versus inpatient management of neutropenia in children with AML.
Conditions
- Acute Myeloid Leukemia
- Neutropenia
- Bacteremia
Sponsors & Collaborators
-
C.S. Mott Children's Hospital
collaborator OTHER -
Children's Healthcare of Atlanta
collaborator OTHER -
Ann & Robert H Lurie Children's Hospital of Chicago
collaborator OTHER -
Children's Medical Center Dallas
collaborator OTHER -
Children's Hospital of Michigan
collaborator OTHER -
Baylor College of Medicine
collaborator OTHER -
University of Mississippi Medical Center
collaborator OTHER -
Arkansas Children's Hospital Research Institute
collaborator OTHER -
Ochsner Health System
collaborator OTHER -
Lucile Packard Children's Hospital
collaborator OTHER -
Primary Children's Hospital
collaborator OTHER -
Rady Children's Hospital, San Diego
collaborator OTHER -
Seattle Children's Hospital
collaborator OTHER -
Patient-Centered Outcomes Research Institute
collaborator OTHER -
Children's Hospital Colorado
collaborator OTHER -
Alfred I. duPont Hospital for Children
collaborator OTHER - collaborator OTHER
-
Children's Hospital of Philadelphia
lead OTHER
Principal Investigators
-
Richard Aplenc, MD, PhD · Children's Hospital of Philadelphia
Eligibility
- Max Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-30
- Primary Completion
- 2019-07-26
- Completion
- 2019-07-26
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
NCT00002499 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00002805 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00186966 ·Status: COMPLETED ·Phase: PHASE3
-
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01235572 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
NCT00002700 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
NCT00022126 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy
NCT02979548 ·Status: UNKNOWN ·Phase: PHASE3
-
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00844441 ·Status: COMPLETED ·Phase: NA
-
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
NCT00962767 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
Transfusion in Adult Acute Myeloid Leukemia
NCT02899767 ·Status: COMPLETED
-
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
NCT04915612 ·Status: COMPLETED ·Phase: PHASE1
-
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024 ·Status: RECRUITING
-
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
NCT02226497 ·Status: TERMINATED ·Phase: NA
-
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
NCT00070174 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00440726 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
NCT00004056 ·Status: COMPLETED ·Phase: PHASE1
-
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
NCT01385787 ·Status: COMPLETED
-
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
NCT05955261 ·Status: SUSPENDED ·Phase: PHASE2
-
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
NCT01743859 ·Status: COMPLETED ·Phase: PHASE2
-
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00002517 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
NCT00005945 ·Status: COMPLETED ·Phase: PHASE3
-
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02666950 ·Status: COMPLETED ·Phase: PHASE2
-
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NCT03310918 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA